Cite
HARVARD Citation
Junge, A. et al. (2018). Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. Hematological oncology. 36 (3), pp. 576-583. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Junge, A. et al. (2018). Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. Hematological oncology. 36 (3), pp. 576-583. [Online].